Skip to main
ABSI
ABSI logo

Absci Corp (ABSI) Stock Forecast & Price Target

Absci Corp (ABSI) Analyst Ratings

Based on 5 analyst ratings
Strong Buy
Strong Buy 60%
Buy 40%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Absci Corp's integration of biologic drug discovery and cell line development positions it uniquely in the therapeutic market, enhancing efficiency and innovation in the creation of novel biologics. A strong clinical activity signal for ABS-101 is projected to increase the probability of success in ulcerative colitis and Crohn's disease, which is pivotal for attracting interest from larger pharmaceutical companies. The anticipated positive readout is expected to validate Absci's broader platform, suggesting an implied potential upside of approximately 30% compared to the base case.

Bears say

Absci Corp faces a negative outlook primarily due to increased dilution arising from recent financing activities, which significantly impacts its valuation. The consistent lowering of the price target to $8 indicates concerns regarding the company's financial health and its ability to maintain shareholder value amid this dilution. Overall, the repeated reference to a diminished price target suggests a cautious approach to Absci’s stock performance moving forward.

Absci Corp (ABSI) has been analyzed by 5 analysts, with a consensus rating of Strong Buy. 60% of analysts recommend a Strong Buy, 40% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Absci Corp and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Absci Corp (ABSI) Forecast

Analysts have given Absci Corp (ABSI) a Strong Buy based on their latest research and market trends.

According to 5 analysts, Absci Corp (ABSI) has a Strong Buy consensus rating as of Oct 15, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $7.98, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $7.98, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Absci Corp (ABSI)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.